SIRT2 and breast cancer: The evaluation of 13e, 13g, and 13h against a panel of tumor cell lines (lymphoma, NSCLC, colon, and breast cancer) suggests SIRT2 as the preferred target for cancer treatment, since the selective SIRT2i 13h is the most potent in terms of cytotoxicity (IC50s = 3–7 μM).333